• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>NCI

NCI

NCI Inc Class A NCIT

Last Price$10.06Day Change (%)-1.37%
Open Price$10.03Day Change ($)-0.14
Day Range9.55–10.0952-Week Range6.02–13.13

As of Mon 12/22/2014 04:00 PM EST | USD

  1. NCI Building Systems Reports Fourth Quarter and 2014 Fiscal Year End Results

    NCI Building Systems Reports Fourth Quarter and 2014 Fiscal Year End Results

  2. NCI Building Systems Announces Fourth Quarter and Fiscal Year End 2014 Earnings Release and Conference Call Schedule

    NCI Building Systems Announces Fourth Quarter and Fiscal Year End 2014 Earnings Release and Conference Call Schedule

  3. NCI Awarded $12 Million Alliant Task Order

    NCI Awarded $12 Million Alliant Task Order

  4. NeoGenomics, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and the Northwestern Medicine Developmental Therapeutics Institute Launch Collaborative Translational Research ...

    NeoGenomics, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and the Northwestern Medicine Developmental Therapeutics Institute Launch Collaborative Translational Research Program

  5. Ipsen Announces That the International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating the Use of Ovarian Suppression to Adjuvant Treatment with Tamoxifen

    Ipsen Announces That the International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating the Use of Ovarian Suppression to Adjuvant Treatment with Tamoxifen

  6. IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

    IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

  7. Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

    Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

  8. IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

    IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

  9. Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

    Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

  10. IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

    IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.